Alemtuzumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Alemtuzumab. Educational only — not medical advice.
Labeled uses
LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS [see Warnings and Precautions (5) ] .
Source: FDA labeling via NIH DailyMed (set 6236b0bc…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.